Breast cancer peptide coverage on Peptide News Digest is dominated by peptide cancer vaccines and peptide-drug conjugates. The most cited 2026 read: BriaCell's Bria-IMT plus checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in a registration-enabling Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy.
Other programs: Greenwich LifeSciences' GP2 / GLSI-100 HER2 peptide vaccine, Roche's breast-cancer pill (part of the Q1 2026 strategy reset), and academic peptide-vaccine work in triple-negative breast cancer.
Stories here cover trial readouts, AACR and ASCO presentations, and the broader immunotherapy pipeline. See #metastatic-breast-cancer, #triple-negative-breast-cancer, and #peptide-vaccine.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
Greenwich LifeSciences presented FLAMINGO-01 Phase III open-label data at AACR 2026 showing GLSI-100 (the 9-amino-acid GP2 HER2 peptide plus GM-CSF adjuvant) produced a ~4x increase in delayed-type hypersensitivity to GP2 across 247 non-HLA-A*02 patients — from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). GP2 is the C-terminal transmembrane fragment of the HER2/neu protein.
BriaCell's Bria-IMT + checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in its pivotal Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy. Phase 2 biomarker analyses identified mitotic circulating tumor cells as prognostic and PD-L1 in tumor-macrophage fusion cells as predictive of checkpoint benefit. Presented at AACR April 20.